PZR/SHP2 signaling seems to be targetable, since the treatment with low dose of the anticancer drug dasatinib, which is a tyrosine kinase inhibitor, leads to inhibition of PZR hyperphosphorylation and reverses the cardiomyopathy and fibrosis in NSML, as well as HCM in NS mice (Yi et al., 2016; Yi et al., 2021). Here, MPZL1 is linked to cardiomyopathy.